

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute Form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet	1	of	1
-------	---	----	---

Complete if Known

Application Number	10/565,885
Filing Date	January 25, 2006
First Named Inventor	LOPEZ DE SILANES, Juan
Art Unit	1618
Examiner Name	<i>To Be Assigned</i>
Attorney Docket Number	2399.0080000/JAG/LAV

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (Of Known)	MM-DD-YYYY		
	US1	4,806,346	02/21/1989	Hum <i>et al.</i>	
	US2	4,814,433	03/21/1989	Fredrickson	
	US3	4,849,352	07/18/1989	Sullivan <i>et al.</i>	
	US4	4,940,670	07/10/1990	Rhodes	
	US5	5,328,834	07/12/1994	Ngo <i>et al.</i>	
	US6	5,443,976	08/22/1995	Carroll	
	US7	5,733,742	03/31/1998	Landon	
	US8	5,888,511	03/30/1999	Skurkovich <i>et al.</i>	
	US9	5,904,922	05/18/1999	Carroll	
	US10	6,333,032	12/25/2001	Skurkovich <i>et al.</i>	
	US11	6,448,054	09/10/2002	Poznansky <i>et al.</i>	
	US12	6,534,059	03/18/2003	Skurkovich <i>et al.</i>	
	US13	6,709,655	03/23/2004	Lopez de Silanes <i>et al.</i>	
	US14	2003/0049725 A1	03/13/2003	Heavner <i>et al.</i>	
	US15	2003/0215448 A1	11/20/2003	Skurkovich <i>et al.</i>	
	US16	2003/0223995 A1	12/04/2003	Skurkovich <i>et al.</i>	
	US17	2003/0224005 A1	12/04/2003	Skurkovich <i>et al.</i>	
	US18	2003/0228310 A1	12/11/2003	Skurkovich <i>et al.</i>	
	US19	2004/0062768 A1	04/01/2004	Skurkovich <i>et al.</i>	
	US20	2004/0086508 A1	05/06/2004	Skurkovich <i>et al.</i>	

FOREIGN PATENT DOCUMENTS

[illegible]

642491_1_1

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

¹EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ²Applicant's unique citation designation number (optional). ³ See Kinds Codes and Patent Classifications at www.uspto.gov or MPEP 901.04. ⁴ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁵ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁶ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁷ Applicant is to place a check mark here if English language translation is attached.

English language translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and possibly prosecute) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case.

Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /Z.S./

Equivalent of Form PTO/SB/08B (09-06)
Approved for use through 03/31/2007. OMB 0651-0031
U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Application Number	10/565,885
		Filing Date	January 25, 2006
		First Named Inventor	LOPEZ DE SILANES, Juan
		Art Unit	1618
		Examiner Name	To Be Assigned
		Attorney Docket Number	2399.0080000/JAG/LAV
Sheet	1 of 4		

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
	NPL1	BECERRIL, B., <i>et al.</i> , "Cloning and characterization of cDNAs that code for Na ⁺ - channel-blocking toxins of the scorpion <i>Centruroides noxius</i> Hoffman," <i>Gene</i> 128:165-171, Elsevier Science Publishers B.V. (1993)	
	NPL2	CAIN, B.S., <i>et al.</i> , "The Physiologic Basis for Anticytokine Clinical Trials in the Treatment of Sepsis," <i>J. Am. Coll. Surg.</i> 186:337-351, American College of Surgeons (1998)	
	NPL3	CALDERON-ARANDA, E.S., <i>et al.</i> , "Neutralizing Capacity of Murine Sera Induced by Different Antigens of Scorpion Venom," <i>Toxicon</i> 31:327-337, Pergamon Press Ltd. (1993)	
	NPL4	CALDERON-ARANDA, E.S., <i>et al.</i> , "The use of synthetic peptides can be a misleading approach to generate vaccines against scorpion toxins," <i>Vaccine</i> 13:1198-1206, Elsevier Science, Ltd. (1995)	
	NPL5	COURAUD, F., <i>et al.</i> , "Two Types of Scorpion Toxin Receptor Sites, One Related to the Activation, the Other to the Inactivation of the Action Potential Sodium Channel," <i>Toxicon</i> 20:9-16, Pergamon Press Ltd. (1982)	
	NPL6	DEHESA-DÁVILA, M. and Possani, L.D., "Scorpionism and Serotherapy in Mexico," <i>Toxicon</i> 32:1015-1018, Elsevier Science Ltd. (1994)	
	NPL7	DEHESA-DÁVILA, M., <i>et al.</i> , "Clinical Toxicology of Scorpion Stings," in <i>Handbook of Clinical Toxicology of Animal Venoms and Poisons</i> , Ch. 18, Meier, J., and White, J., eds., CRC Press, Boca Raton, FL, pp. 221-238 (1995)	
	NPL8	Abstract of DICK, A.D., <i>et al.</i> , "Neutralizing TNF-alpha Activity Modulates T-cell Phenotype and Function in Experimental Autoimmune Uveoretinitis," <i>J. Autoimmun.</i> 11:255-264 (1998)	
	NPL9	EDMAN, P. and Begg, G., "A Protein Sequenator," <i>Eur. J. Biochem.</i> 1:80-91, Blackwell Science, Ltd. on behalf of the Federation of European Biochemical Societies (1967)	
	NPL10	FEKADE, D., <i>et al.</i> , "Prevention of Jarisch-Herxheimer Reactions by Treatment with Antibodies Against Tumor Necrosis Factor α ," <i>N. Engl. J. Med.</i> 335:311-315, Massachusetts Medical Society (1996)	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

ALL REFERENCES CONSIDERED EXCEPT WHERE USED THROUGH. /Z.S./

Equivalent of Form PTO/SB/06B (09-06)
Approved for use through 03/31/2007. CMB 0651-0031
U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Application Number	10/565,885
				Filing Date	January 25, 2006
				First Named Inventor	LOPEZ DE SILANES, Juan
				Art Unit	1618
				Examiner Name	To Be Assigned
Sheet	2	of	4	Attorney Docket Number	2399.0080000/JAG/LAV

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number, publisher, city and/or country where published	T ²
	NPL11	FOX, D.A., "Cytokine Blockade as a New Strategy to Treat Rheumatoid Arthritis," <i>Arch. Intern. Med.</i> 160:437-444, American Medical Association (2000)	
	NPL12	GARCÍA, C., et al., "Isolation, Characterization and Comparison of Novel Crustacean Toxin with a Mammalian Toxin from the Venom of the Scorpion <i>Centruroides noxius</i> Hoffman," <i>Comp. Biochem. Physiol.</i> 116B:315-322, Elsevier Science, Inc. (1997)	
	NPL13	KRUEGER, J.G., "The immunologic basis for the treatment of psoriasis with new biologic agents," <i>J. Am. Acad. Dermatol.</i> 46:1-23, American Academy of Dermatology, Inc. (January 2002)	
	NPL14	LEGROS, C., et al., "Use of fusion protein constructs to generate potent immunotherapy and protection against scorpion toxins," <i>Vaccine</i> 20:934-942, Elsevier Science, Ltd. (2002)	
	NPL15	LICEA, A.F., et al., "FAB Fragments of the Monoclonal Antibody BCF2 are Capable of Neutralizing the Whole Venom from the Scorpion <i>Centruroides noxius</i> Hoffman," <i>Toxicon</i> 34:843-847, Elsevier Science Ltd. (1996)	
	NPL16	LISMAN, K.A., et al., "Managing Heart Failure with Immunomodulatory Agents," <i>Cardiol. Clin.</i> 19:617-625, W.B. Saunders Co. (2001)	
	NPL17	LUGER, T., "Treatment of immune-mediated skin diseases: future perspectives," <i>Eur. J. Dermatol.</i> 11:343-347, accessed at http://www.john-libbey-eurotext.fr/en/revues/medecine/ejd/e-docs/00/01/88/A6/article.md , John Libbey Eurotext (2001)	
	NPL18	MARABOTO MARTINEZ, J.A., et al., "Panorama Epidemiológico de las Intoxicaciones Causadas por Animales Ponzosñosos en la Población Derechohabiente del IMSS 1990-1998," in <i>3ª Reunión de Expertos en Envenenamiento por Animales Ponzosñosos</i> , Instituto de Biotecnología, Universidad Nacional Autónoma de México, Alcapulco, Gro., México (February 17-19, 1999)	
	NPL19	English translation of Maraboto Martinez, J.A., et al., "Panorama Epidemiológico de las Intoxicaciones Causadas por Animales Ponzosñosos en la Población Derechohabiente del IMSS 1990-1998," in <i>3ª Reunión de Expertos en Envenenamiento por Animales Ponzosñosos</i> , Instituto de Biotecnología, Universidad Nacional Autónoma de México, Alcapulco, Gro., México (February 17-19, 1999)	
	NPL20	MARTIN, G.S., "Current Management Strategies for Severe Sepsis and Septic Shock," Presented at Chest 2001: 67th Annual Scientific Assembly of the American College of Chest Physicians, November 4-8, 2001, Philadelphia, PA, accessed online at http://www.medscape.com/viewarticle/412927 , Medscape Portals, Inc., 4 pages (2001)	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The applicant is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

ALL REFERENCES CONSIDERED EXCEPT WHERE NOT INDICATED OTHERWISE THROUGHOUT. /Z.S./

Equivalent of Form PTO/SB/06B (09-06)

Approved for use through 03/31/2007. OMB 0651-0031

U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Application Number	10/565,885
		Filing Date	January 25, 2006
		First Named Inventor	LOPEZ DE SILANES, Juan
		Art Unit	1618
		Examiner Name	To Be Assigned
Sheet	3 of 4	Attorney Docket Number	2399.0080000/JAG/LAV

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
	NPL21	NONNER, W., "Effects of <i>Leiurus</i> Scorpion Venom on the "Gating" Current in Myelinated Nerve," <i>Adv. Cytopharmacol.</i> 3:345-352, Raven Press (1979)	
	NPL22	POSSANI, L.D., et al., "Scorpion toxins from <i>Centruroides noxius</i> and <i>Tityus serrulatus</i> ," <i>Biochem. J.</i> 229:739-750, Biochemical Society/Portland Press (1985)	
	NPL23	POSSANI, L.D., et al., "Scorpion toxins specific for Na ⁺ -channels," <i>Eur. J. Biochem.</i> 264:287-300, Blackwell Science, Ltd. on behalf of the Federation of European Biochemical Societies (1999)	
	NPL24	POSSANI, L.D., et al., "Peptides and genes coding for scorpion toxins that affect ion-channels," <i>Biochimie</i> 82:861-868, Editions Scientifiques Elsevier (2000)	
	NPL25	PRESENT, D.H., et al., "Infliximab for the Treatment of Fistulas in Patients with Crohn's Disease," <i>N. Engl. J. Med.</i> 340:1398-1405, Massachusetts Medical Society (1999)	
	NPL26	QIAN, Y., et al., "Topical Soluble Tumor Necrosis Factor Receptor Type I Suppresses Ocular Chemokine Gene Expression and Rejection of Allogeneic Corneal Transplants," <i>Arch. Ophthalmol.</i> 118:1666-1671, American Medical Association (2000)	
	NPL27	STAPCZYNSKI, J.S., "Shock, Septic," Dire, D.J., et al., eds., eMedicine.com Inc., accessed online at http://emedicine.com/EMERG/topic533.htm , eMedicine.com, Inc., 25 pages (2004)	
	NPL28	STRICHARTZ, G., et al., "An Integrated View of the Molecular Toxinology of Sodium Channel Gating in Excitable Cells," <i>Ann. Rev. Neurosci.</i> 10:237-267, Annual Reviews, Inc. (1987)	
	NPL29	TORRES, P.F., and KIJLSTRA, A., "The role of cytokines in corneal immunopathology," <i>Ocul. Immunol. Inflamm.</i> 9:9-24, Swets & Zeitlinger (2001)	
	NPL30	ZAMUDIO, F., et al., "Amino acid sequence and immunological characterization with monoclonal antibodies of two toxins from the venom of the scorpion <i>Centruroides noxius</i> Hoffman," <i>Eur. J. Biochem.</i> 204:281-292, Blackwell Science, Ltd. on behalf of the Federation of European Biochemical Societies (1992)	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

ALL REFERENCES CONSIDERED EXCEPT WHERE INDICATED THROUGHOUT. /Z.S./

Equivalent of Form PTO/SB/088 (09-06)
 Approved for use through 03/31/2007. OMB 0651-0031
 U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO			Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)			Application Number	10/565,885
			Filing Date	January 25, 2006
			First Named Inventor	LOPEZ DE SILANES, Juan
			Art Unit	1618
			Examiner Name	To Be Assigned
			Attorney Docket Number	2399.0080000/JAG/LAV
Sheet	4	of	4	

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published		T ²
	NPL31	ZHU, S., et al., "Early Expression of Proinflammatory Cytokines Interleukin-1 and Tumor Necrosis Factor- α after Corneal Transplantation," <i>J. Interferon. Cytokine. Res.</i> 19:661-669, Mary Ann Liebert, Inc. (1999)		
	NPL32	International Search Report for International Patent Application No. PCT/MX02/00013, European Patent Office, Netherlands, mailed on August 16, 2002		
	NPL33	Dialog File 351, Accession No. 9271133, Derwent WPI English language abstract for Spanish Patent No. 2 106 183 (Document FP1)		
	NPL34	English language translation of Secretaría de Salud, "Pyrogen Tests," in: <i>Farmacopea de los Estados Unidos Mexicanos</i> , Vol. I, Secretaría de Salud, Mexico City, MX, pp. 334-335 (2000)		
	NPL35	English language translation of Secretaría de Salud, "Potency of Anti-Poison Sera," in <i>Farmacopea de los Estados Unidos Mexicanos</i> , Vol. II, Secretaría de Salud, Mexico City, MX, pp. 1756-1757 (2000)		

642463_1

Examiner Signature	/Zachary Skelding/	Date Considered	08/16/2008
--------------------	--------------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

ALL REFERENCES CONSIDERED EXCEPT WHERE USED THROUGH. /Z.S./